Express News | Adial Pharmaceuticals FY 2024 GAAP EPS $(2.72) Beats $(2.97) Estimate

BenzingaMar 4 09:50 ET

10-K: FY2024 Annual Report

SECMar 4 08:50 ET · Announcements

Adial Pharmaceuticals Expects Cash to Fund Operations Into 2H of 2025

TipRanksMar 4 08:36 ET

Adial Pharma Believes Existing Cash and Cash Equivalents Will Fund Oper Expenses Into 2H

Dow JonesMar 4 08:31 ET

Express News | Adial Pharmaceuticals FY Net Income USD -13.2 Million

ReutersMar 4 08:30 ET

Adial Pharmaceuticals Shares Are Trading Higher After the Company Announced It Received FDA Feedback for Its Vitro Bridging Strategy of AD04 and Will Proceed to Manufacture Clinical Supplies for Its Upcoming Phase 3 Clinical Trial.

BenzingaFeb 25 09:05 ET

Express News | Adial Pharmaceuticals Receives Positive Response From FDA Meeting Regarding Proposed in Vitro Bridging Strategy for Ad04

ReutersFeb 25 09:00 ET

Adial Pharmaceuticals Receives Positive Response From FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

GlobeNewswireFeb 25 09:00 ET

EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder

BenzingaFeb 25 08:30 ET

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

GlobeNewswireFeb 12 09:00 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'New Patent Expands Patent Estate Covering Adial's Unique Molecular Genetic Approach to Diagnosing and Potentially Treating Alcohol and Drug Dependence'

BenzingaFeb 12 08:30 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga Co. Awarded New U.S Patent Covering Genotype-Specific Treatment Of Opioid -Related Disorders

BenzingaFeb 12 08:30 ET

EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

BenzingaFeb 12 08:30 ET

EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder

BenzingaJan 29 08:31 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Safety and Tolerability Consistent With Ondansetron's Extensive Human Use Experience'

BenzingaJan 29 08:30 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Adial's Formulation Exhibited Predictable Bioavailability Relative to the Reference Standard; Near-micro Doses Exhibited Dose Proportionality in Pharmacokinetic Exposure, and No Food Effect'

BenzingaJan 29 08:30 ET

Express News | EXCLUSIVE: Adial Pharmaceuticals Tells Benzinga 'Completion Enables the End-of-Phase 2 (EOP2) Interaction With the FDA on the Design of the Phase 3 Program and Is Expected to Facilitate Ongoing Partnership Discussions'

BenzingaJan 29 08:30 ET

Adial Pharmaceuticals Focuses on Strategic Growth Initiatives

TipRanksJan 13 09:02 ET

Adial Pharmaceuticals' New Purchase Agreement With Alumni Capital

TipRanksDec 18, 2024 17:34 ET

Express News | Adial Pharmaceuticals Inc - Can Sell up to $10 Million in Shares

ReutersDec 18, 2024 17:02 ET